Biomarkers
“The word 'biomarker' is short for 'biological marker', or indicator. It could be a change in a gene in the tumour's DNA, or it could be a molecule produced by the tumour. The presence or absence of particular gene changes or molecules (biomarkers) can give your health team more information about your tumour.“
https://www.thebraintumourcharity.org/u ... iomarkers/
The main tests for brain tumours
Re: The main tests for brain tumours
MGMT methylation test
The MGMT methylation test can be useful in:
predicting how effective chemotherapy treatment is likely to be for you.
Your tumour may be suitable for this test if it is one of the following:
Anaplastic glioma
Anaplastic astrocytoma
Anaplastic oligodendroglia
Anaplastic oligoastrocytoma
Glioblastoma
The MGMT methylation test can be useful in:
predicting how effective chemotherapy treatment is likely to be for you.
Your tumour may be suitable for this test if it is one of the following:
Anaplastic glioma
Anaplastic astrocytoma
Anaplastic oligodendroglia
Anaplastic oligoastrocytoma
Glioblastoma
Debbie
Re: The main tests for brain tumours
From the below discussion (linked)
Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494935
/
“Low MGMT expression, a temozolomide associated biomarker, was noted in a variety of sarcomas including alveolar soft part sarcoma (21 ASPS), desmoid, EHE, perivascular epithelioid cell tumor (PEComa), endometrial stromal sarcoma (ESS), giant cell tumor, liposarcoma, LMS, malignant peripheral nerve sheath tumor (MPNST), osteosarcoma and UPS. There was low expression of MGMT in 65.3% of the sarcomas overall.”
http://www.cureasps.org/forum/viewtopic ... 531#p11739
Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494935
/
“Low MGMT expression, a temozolomide associated biomarker, was noted in a variety of sarcomas including alveolar soft part sarcoma (21 ASPS), desmoid, EHE, perivascular epithelioid cell tumor (PEComa), endometrial stromal sarcoma (ESS), giant cell tumor, liposarcoma, LMS, malignant peripheral nerve sheath tumor (MPNST), osteosarcoma and UPS. There was low expression of MGMT in 65.3% of the sarcomas overall.”
http://www.cureasps.org/forum/viewtopic ... 531#p11739
Debbie
Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis
Abstract
O6-Methylguanine-DNA-methyltransferase (MGMT) is a unique protein, which both repairs O6-alkylguanine lesions stoichiometrically without a multi-enzymatic pathway and self-inactivates. It has recently been linked to the therapeutic success of alkylating agent chemotherapy, specifically temozolomide treatment. This drug affects the MGMT pathway to induce cell death in tumor tissue. Low levels of functional MGMT have been correlated with success of treatment, while high levels bring about failure of therapy. Expression of MGMT protein varies in normal and tumoral tissue. Furthermore, its epigenetic silencing due to promoter methylation has been linked to its lack of expression in many types of tumor, including gliomas. Great enthusiasm surrounds the utility of this protein in cancer treatment. Not only has there been success in manipulating MGMT levels to enhance alkylating agent therapy, but studies also suggest a possible role of MGMT in protecting hematopoietic cells from the myelosuppressive effects of high-dose chemotherapy. Innovative research into this protein will no doubt be rewarding. This review presents a summary of what is known about this unique protein, including its structure, function in its pathway, polymorphisms, expression in normal and tumoral tissue, relation to alkylating agent therapy, and possible future applications.
http://ar.iiarjournals.org/content/29/10/3759.full
O6-Methylguanine-DNA-methyltransferase (MGMT) is a unique protein, which both repairs O6-alkylguanine lesions stoichiometrically without a multi-enzymatic pathway and self-inactivates. It has recently been linked to the therapeutic success of alkylating agent chemotherapy, specifically temozolomide treatment. This drug affects the MGMT pathway to induce cell death in tumor tissue. Low levels of functional MGMT have been correlated with success of treatment, while high levels bring about failure of therapy. Expression of MGMT protein varies in normal and tumoral tissue. Furthermore, its epigenetic silencing due to promoter methylation has been linked to its lack of expression in many types of tumor, including gliomas. Great enthusiasm surrounds the utility of this protein in cancer treatment. Not only has there been success in manipulating MGMT levels to enhance alkylating agent therapy, but studies also suggest a possible role of MGMT in protecting hematopoietic cells from the myelosuppressive effects of high-dose chemotherapy. Innovative research into this protein will no doubt be rewarding. This review presents a summary of what is known about this unique protein, including its structure, function in its pathway, polymorphisms, expression in normal and tumoral tissue, relation to alkylating agent therapy, and possible future applications.
http://ar.iiarjournals.org/content/29/10/3759.full
Debbie